06:17 AM EDT, 10/23/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday that the Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for its injection, Kisunla, for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease in eligible adults in Great Britain.

The company said eligible patients are specifically limited to apolipoprotein heterozygotes or non-carriers, which is consistent with the requirements for currently approved amyloid-targeting therapies in the region.

The company said these individuals can receive intravenous infusion treatment every four weeks.

Price: 906.22, Change: -2.93, Percent Change: -0.32